ES2639026T3 - Anticuerpos totalmente humanos específicos para CADM1 - Google Patents

Anticuerpos totalmente humanos específicos para CADM1 Download PDF

Info

Publication number
ES2639026T3
ES2639026T3 ES10708470T ES10708470T ES2639026T3 ES 2639026 T3 ES2639026 T3 ES 2639026T3 ES 10708470 T ES10708470 T ES 10708470T ES 10708470 T ES10708470 T ES 10708470T ES 2639026 T3 ES2639026 T3 ES 2639026T3
Authority
ES
Spain
Prior art keywords
cadm1
human antibodies
antibodies specific
totally human
ident
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10708470T
Other languages
English (en)
Inventor
Jonathan Alexander Terrett
Heidi Leblanc
Haichun Huang
Erika Meaddough
Chin Pan
Bingliang Chen
Chetana Rao-Naik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biotherapeutics Ltd
ER Squibb and Sons LLC
Original Assignee
Oxford Biotherapeutics Ltd
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biotherapeutics Ltd, ER Squibb and Sons LLC filed Critical Oxford Biotherapeutics Ltd
Application granted granted Critical
Publication of ES2639026T3 publication Critical patent/ES2639026T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Abstract

Un anticuerpo monoclonal aislado, o una porción de unión a antígeno de este, o un fragmento de anticuerpo que se une a un epítopo en CADM1 humano y comprende una región variable de la cadena pesada que comprende la secuencia de aminoácidos expuesta en la sec. con núm. de ident.: 19, 20 o 21 y una región variable de la cadena ligera que comprende la secuencia de aminoácidos expuesta en la sec. con núm. de ident.: 22, 23, o 24.
ES10708470T 2009-03-05 2010-03-05 Anticuerpos totalmente humanos específicos para CADM1 Active ES2639026T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20947109P 2009-03-05 2009-03-05
US20939009P 2009-03-05 2009-03-05
PCT/US2010/026315 WO2010102175A1 (en) 2009-03-05 2010-03-05 Fully human antibodies specific to cadm1

Publications (1)

Publication Number Publication Date
ES2639026T3 true ES2639026T3 (es) 2017-10-25

Family

ID=42144944

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10708470T Active ES2639026T3 (es) 2009-03-05 2010-03-05 Anticuerpos totalmente humanos específicos para CADM1

Country Status (25)

Country Link
US (2) US8420084B2 (es)
EP (1) EP2403878B1 (es)
JP (1) JP5816558B2 (es)
KR (1) KR101769160B1 (es)
CN (1) CN102341412B (es)
AU (1) AU2010221186B2 (es)
BR (1) BRPI1009232B1 (es)
CA (1) CA2753702C (es)
CY (1) CY1119539T1 (es)
DK (1) DK2403878T3 (es)
EA (1) EA028336B1 (es)
ES (1) ES2639026T3 (es)
HR (1) HRP20171274T1 (es)
HU (1) HUE034196T2 (es)
IL (1) IL214779A (es)
LT (1) LT2403878T (es)
ME (1) ME02842B (es)
MX (1) MX2011009220A (es)
NZ (1) NZ594682A (es)
PL (1) PL2403878T3 (es)
PT (1) PT2403878T (es)
SG (1) SG173742A1 (es)
UA (1) UA102891C2 (es)
WO (1) WO2010102175A1 (es)
ZA (1) ZA201105918B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989160B2 (en) 2006-02-13 2011-08-02 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
ES2625259T3 (es) * 2006-08-29 2017-07-19 Oxford Biotherapeutics Ltd Identificación de proteína asociada con carcinoma hepatocelular, glioblastoma y cáncer de pulmón
BRPI1009232B1 (pt) * 2009-03-05 2022-05-03 E.R. Squibb & Sons, Llc. Anticorpo monoclonal isolado ou uma porção de ligação de antígeno do mesmo, ou um fragmento de anticorpo, composição que os compreende, molécula de ácido nucleico, hibridoma e métodos para a preparação de um anticorpo anti-cadm1
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
CA2928851A1 (en) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
JP6440968B2 (ja) * 2013-05-28 2018-12-19 国立大学法人 宮崎大学 ＩｇＳＦ４／ＴＳＬＣ１／ＣＡＤＭ１を特異的に認識できる抗体
US11208483B2 (en) * 2015-11-19 2021-12-28 Shanghai Kanda Biotechnology Co, Ltd. CTLA-4 antibodies and uses thereof
JP7229503B2 (ja) 2018-03-16 2023-02-28 国立大学法人 東京大学 ＣＡＤＭ１ｖ９認識抗体
CA3117240A1 (en) * 2018-10-22 2020-04-30 Shanghai GenBase Biotechnology Co., Ltd. Anti-cldn18.2 antibody and uses thereof
WO2022239766A1 (ja) * 2021-05-11 2022-11-17 国立大学法人 東京大学 抗ｃａｄｍ１抗体
TW202321296A (zh) * 2021-10-06 2023-06-01 美商鏈接免疫療法公司 抗間皮素抗原結合分子及其用途
KR20230061710A (ko) 2021-10-29 2023-05-09 주식회사 이뮤노로지컬디자이닝랩 Cadm1을 인식하는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물
KR20230062691A (ko) 2021-10-29 2023-05-09 주식회사 이뮤노로지컬디자이닝랩 Cadm1에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
WO2023163094A1 (ja) * 2022-02-25 2023-08-31 日本電気株式会社 成人ｔ細胞白血病の治療又は予防のための医薬組成物
JP7270944B1 (ja) * 2022-09-13 2023-05-11 学校法人近畿大学 抗ｃａｄｍ１抗体またはその抗原結合断片

Family Cites Families (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US5144011A (en) 1981-06-26 1992-09-01 Boston University Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4698420A (en) 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6261774B1 (en) 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US5864026A (en) 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5712375A (en) 1990-06-11 1998-01-27 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5763566A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US5789157A (en) 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DE69233408T2 (de) 1991-12-02 2005-09-22 Cambridge Antibody Technology Ltd., Melbourn Herstellung von Antikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken.
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
CA2645735A1 (en) 1995-05-03 1996-11-07 Gilead Science, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
NZ321172A (en) 1995-10-03 2000-02-28 Scripps Research Inst CBI analogs of CC-1065 and the duocarmycins
US6642360B2 (en) 1997-12-03 2003-11-04 Genentech, Inc. Secreted polypeptides that stimulate release of proteoglycans from cartilage
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US7411051B2 (en) 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
JP2002503228A (ja) 1997-05-22 2002-01-29 ザ スクリップス リサーチ インスティテュート デュオカルマイシンおよびｃｃ−１０６５の類似体
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
NZ527900A (en) 1997-12-03 2005-02-25 Genentech Inc PRO361 polypeptides and nucleic acids with homology to mucin and chitinase
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
WO1999057132A1 (en) 1998-05-07 1999-11-11 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
AU776825B2 (en) 1998-08-07 2004-09-23 Immunex Corporation Molecules designated LDCAM
ATE415480T1 (de) 1998-08-07 2008-12-15 Immunex Corp B7l-1 moleküle
EP1124850A4 (en) 1998-10-28 2005-10-19 Human Genome Sciences Inc 12 HUMAN SECRETATED PROTEINS
US20030055231A1 (en) 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
AU1618500A (en) 1998-11-12 2000-05-29 Incyte Pharmaceuticals, Inc. Human cell surface receptor proteins
EP1135495A2 (en) 1998-12-01 2001-09-26 Genentech, Inc. Secreted amd transmembrane polypeptides and nucleic acids encoding the same
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
KR100504305B1 (ko) 1999-03-23 2005-07-28 제넨테크, 인크. 분비 및 막횡단 폴리펩티드 및 이를 코딩하는 핵산
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7129338B1 (en) 1999-07-08 2006-10-31 Research Association For Biotechnology Secretory protein or membrane protein
US6387620B1 (en) 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
MXPA02000962A (es) 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
EP2829609A1 (en) 1999-08-24 2015-01-28 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002014577A1 (fr) * 2000-08-04 2002-02-21 Japan Lifeline Co., Ltd Procede pour produire un element metallique cylindrique a paroi mince
CA2419529C (en) 2000-08-15 2013-02-12 The John Hopkins University School Of Medicine Diagnosis and treatment of tumor-suppressor associated disorders
CA2421122A1 (en) 2000-09-01 2002-03-07 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
WO2002047466A2 (en) * 2000-10-27 2002-06-20 The Johns Hopkins University School Of Medicine Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof
WO2002066643A2 (en) 2000-11-13 2002-08-29 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20060223114A1 (en) 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
CA2444854A1 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
CA2508763C (en) 2001-05-11 2012-01-24 Kirin Beer Kabushiki Kaisha Human antibody producing mouse and method for producing human antibody using the same
WO2002092780A2 (en) 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US7129261B2 (en) 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
EP1404356B1 (en) 2001-06-11 2011-04-06 Medarex, Inc. Method for designing cd10-activated prodrug compounds
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
WO2004058821A2 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
JP2005502703A (ja) 2001-09-07 2005-01-27 ザ スクリプス リサーチ インスティテュート Ｃｃ−１０６５およびデュオカルマイシンのｃｂｉ類似体
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
PT1517921E (pt) 2002-06-28 2006-09-29 Domantis Ltd Ligandos duplamente especificos com semi-vida no soro aumentada
AU2003286003B2 (en) 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
EP1594893A2 (en) 2003-02-14 2005-11-16 Sagres Discovery, Inc. Therapeutic targets in cancer
ES2298467T3 (es) * 2003-03-31 2008-05-16 Stichting Researchfonds Pathologie Deteccion de canceres invasivos inducidos por hpv y sus lesiones precursoras con potencial invasivo.
DE10316701A1 (de) 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
WO2004091517A2 (en) 2003-04-15 2004-10-28 Smithkline Beecham Corporation Conjugates comprising human il-18 and substitution mutants thereof
AU2004239065B2 (en) 2003-05-14 2008-05-15 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
PT1639011E (pt) 2003-06-30 2009-01-20 Domantis Ltd Anticorpos (dab) de domínio único peguilados
CA2533512C (en) 2003-07-25 2013-06-11 Amgen Inc. Antagonists and agonists of ldcam and methods of use
US7807392B1 (en) 2003-09-15 2010-10-05 Celera Corporation Lung disease targets and uses thereof
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
JP4227881B2 (ja) 2003-11-13 2009-02-18 財団法人宮崎県産業支援財団 成人ｔ細胞白血病診断薬
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1747021B1 (en) 2004-05-19 2015-09-09 E. R. Squibb & Sons, L.L.C. Self-immolative linkers and drug conjugates
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
EP1791565B1 (en) 2004-09-23 2016-04-20 Genentech, Inc. Cysteine engineered antibodies and conjugates
US7947866B2 (en) 2004-10-29 2011-05-24 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
AU2005307789A1 (en) 2004-11-16 2006-05-26 Avidia Research Institute Protein scaffolds and uses thereof
EP1844073A1 (en) 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US8048992B2 (en) * 2005-02-28 2011-11-01 Institute For Antibodies Co., Ltd. Anti-IgSF4 antibody and utilization of the same
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
JP4536588B2 (ja) 2005-05-11 2010-09-01 財団法人宮崎県産業支援財団 成人ｔ細胞白血病の診断器具
US7842467B1 (en) 2005-05-12 2010-11-30 Celera Corporation Breast disease targets and uses thereof
JP5131946B2 (ja) 2005-09-13 2013-01-30 国立大学法人 東京大学 がんの診断、処置および／または予防、および／または浸潤・転移の抑制のための方法、システムおよび組成物ならびに関連するスクリーニング方法
CN101312748A (zh) 2005-09-26 2008-11-26 梅达莱克斯公司 抗体-药物轭合物和使用方法
AU2006294644A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
ES2375843T3 (es) 2005-10-26 2012-03-06 Medarex, Inc. Procedimientos y compuestos para la preparación de an�?logos de cc-1065.
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
EP1973576B1 (en) 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2007074832A1 (ja) 2005-12-28 2007-07-05 Japan Health Sciences Foundation 小細胞肺がんの診断のための方法、システムおよび組成物ならびに関連するスクリーニング方法
US7842291B1 (en) 2006-05-22 2010-11-30 Celera Corporation Methods and compositions for diagnosing and treating diseases
JP5382692B2 (ja) 2006-07-10 2014-01-08 学校法人藤田学園 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
US8586006B2 (en) 2006-08-09 2013-11-19 Institute For Systems Biology Organ-specific proteins and methods of their use
ES2625259T3 (es) * 2006-08-29 2017-07-19 Oxford Biotherapeutics Ltd Identificación de proteína asociada con carcinoma hepatocelular, glioblastoma y cáncer de pulmón
EP2092074A4 (en) 2006-11-02 2010-06-09 Univ Yale ESTIMATION OF OOCYTE COMPETENCE
EP1918299A1 (en) 2006-11-03 2008-05-07 Universite De Geneve Modulators of cell adhesion molecules and use thereof
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
US20100330558A1 (en) 2007-04-06 2010-12-30 Bankaitis-Davis Danute M Gene Expression Profiling for Identification, Monitoring and Treatment of Cervical Cancer
WO2008142693A2 (en) 2007-05-22 2008-11-27 Yeda Research And Development Co. Ltd. Regulation of myelination by nectin-like (necl) molecules
EP2185933B1 (en) * 2007-08-07 2015-10-07 Oxford Biotherapeutics Ltd. Matriptase protein and uses thereof
WO2009029883A2 (en) 2007-08-30 2009-03-05 Genentech, Inc. Methods and compositions for modulating t cells
WO2009040782A2 (en) 2007-09-28 2009-04-02 Royal College Of Surgeons In Ireland A method of assessing colorectal cancer status in an individual
EP2128259A1 (en) 2008-05-27 2009-12-02 Koninklijke Philips Electronics N.V. Therapy delivery and monitoring using a gene of interest-reporter fusion protein and optical imaging
CA2750818A1 (en) 2009-01-27 2010-08-05 Proteogenix, Inc. Biomarkers for detection of neonatal sepsis in biological fluid
BRPI1009232B1 (pt) 2009-03-05 2022-05-03 E.R. Squibb & Sons, Llc. Anticorpo monoclonal isolado ou uma porção de ligação de antígeno do mesmo, ou um fragmento de anticorpo, composição que os compreende, molécula de ácido nucleico, hibridoma e métodos para a preparação de um anticorpo anti-cadm1

Also Published As

Publication number Publication date
US20130156788A1 (en) 2013-06-20
EA028336B1 (ru) 2017-11-30
AU2010221186B2 (en) 2013-08-22
KR20110126739A (ko) 2011-11-23
IL214779A (en) 2015-11-30
JP5816558B2 (ja) 2015-11-18
US8420084B2 (en) 2013-04-16
AU2010221186A1 (en) 2011-09-08
BRPI1009232A2 (pt) 2021-01-26
HUE034196T2 (en) 2018-02-28
HRP20171274T1 (hr) 2017-10-20
CA2753702C (en) 2017-01-03
PT2403878T (pt) 2017-09-01
EA201101242A1 (ru) 2012-04-30
DK2403878T3 (en) 2017-09-18
SG173742A1 (en) 2011-09-29
KR101769160B1 (ko) 2017-08-17
ME02842B (me) 2018-01-20
CN102341412A (zh) 2012-02-01
NZ594682A (en) 2013-06-28
EP2403878A1 (en) 2012-01-11
MX2011009220A (es) 2011-09-28
CY1119539T1 (el) 2018-03-07
PL2403878T3 (pl) 2017-12-29
EP2403878B1 (en) 2017-06-14
JP2012519492A (ja) 2012-08-30
BRPI1009232B1 (pt) 2022-05-03
CN102341412B (zh) 2018-01-05
WO2010102175A1 (en) 2010-09-10
ZA201105918B (en) 2012-10-31
LT2403878T (lt) 2017-10-10
US20120093826A1 (en) 2012-04-19
IL214779A0 (en) 2011-11-30
CA2753702A1 (en) 2010-09-10
UA102891C2 (uk) 2013-08-27

Similar Documents

Publication Publication Date Title
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
ES2525477T3 (es) Anticuerpos anti-factor D humanizados
AR083747A1 (es) Anticuerpos anti-il-23
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
PE20150023A1 (es) Proteinas de union a antigeno st2
ES2621874T3 (es) Anticuerpos para MUC16 y métodos de uso de los mismos
ES2684475T3 (es) Proteínas que se unen a beta amiloide
CL2011003148A1 (es) Proteina biespecifica de union a antigeno, que comprende a)2 cadenas ligeras y 2 cadenas pesadas de un anticuerpo que se une especificamente a un antigeno y 2 fragmentos fab, b)dos fragmentos fab adicionales de un anticuerpo que se une especificamente a un segundo antigeno; metodo de preparacion; composicion farmaceutica y uso.
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
NZ600022A (en) Anti CD37 antibodies
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
PE20180042A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
CL2012003245A1 (es) Proteína de unión a antígeno aislada que se une a linfopoyetina estromal tímica (tslp); composición que comprende una proteína de unión a antígeno que une tslp correspondiente a un anticuerpo humano anti-tslp.
RS52782B (en) HIGH AFINITY HUMAN ANTIBODIES FOR THE HUMAN IL-4 RECEPTOR
EA201591153A1 (ru) Антитела, связывающиеся с tl1a, и их применение
NZ597447A (en) Humanised antibodies to toll-like receptor 2 and uses thereof
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
NZ720765A (en) Antibodies and methods of use
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
AR105267A1 (es) Anticuerpos de unión a tau
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
AR073140A1 (es) Anticuerpos anti-il-23r disenados
AR099604A1 (es) Anticuerpos de metaloproteinasa de matriz 9 y sus métodos de uso